{"organizations": ["Companion Diagnostic Market"], "uuid": "aec80b425c93dbb7a8f637e6a0dbce174e3c8292", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.bio-medicine.org", "main_image": "", "site_section": "http://www.bio-medicine.org/inc/biomed/medicine-technology.asp", "section_title": "Latest Medical Technology from Bio-Medicine.Org", "url": "http://www.bio-medicine.org/medicine-technology-1/Global-Personalized-Medicine--Targeted-Therapeutics-and-Companion-Diagnostic-Market-2015-2019---Key-Strengths--Weaknesses-and-Threats-Influencing-Lead-48816-1/", "country": "US", "title": "Global Personalized Medicine, Targeted Therapeutics and Companion Diagnostic Market 2015-2019 - Key Strengths, Weaknesses and Threats Influencing Leading Player Position within the Market", "performance_score": 0, "site": "bio-medicine.org", "participants_count": 0, "title_full": "Global Personalized Medicine, Targeted Therapeutics and Companion Diagnostic Market 2015-2019 - Key Strengths, Weaknesses and Threats Influencing Leading Player Position within the Market", "spam_score": 0.0, "site_type": "news", "published": "2015-10-12T20:04:00.000+03:00", "replies_count": 0, "uuid": "aec80b425c93dbb7a8f637e6a0dbce174e3c8292"}, "author": "", "url": "http://www.bio-medicine.org/medicine-technology-1/Global-Personalized-Medicine--Targeted-Therapeutics-and-Companion-Diagnostic-Market-2015-2019---Key-Strengths--Weaknesses-and-Threats-Influencing-Lead-48816-1/", "ord_in_thread": 0, "title": "Global Personalized Medicine, Targeted Therapeutics and Companion Diagnostic Market 2015-2019 - Key Strengths, Weaknesses and Threats Influencing Leading Player Position within the Market", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "Date:10/12/2015 \nDUBLIN , Oct. 12 2015 /PRNewswire/ -- \nResearch and Markets ( http://www.researchandmarkets.com/research/mjpkxt/personalized ) has announced the addition of the \"Personalized Medicine, Targeted Therapeutics and Companion Diagnostic Market to 2019 - Strategic Analysis of Industry Trends, Technologies, Participants, and Environment\" report to their offering. \nThis market is made up of companion diagnostics and targeted therapeutics and is currently worth $42 billion. This market is dominated by oncology, cardiovascular and infectious disease treatment and diagnostics. The report Personalized Medicine, Targeted Therapeutics and Companion Diagnostic Market: Strategic Analysis of Industry Trends, Technologies, Participants, and Environment' has already been procured by 17 of the top 25 Pharma companies globally. In this newly published edition, it is a revolutionary insight into the vertical growing market of personalized healthcare globally. \nThe personalized medicine (global & USA ) market is presented as follows: - By Company (e.g., Qiagen, AFFYMETRIX, ATOSSA GENETICS, NODALITY, deCode /Amgen, CELERA, MYRIAD) - By Geography (US, UK, EU) - By Segment (Targeted therapeutics, Companion Diagnostics) - By Sub-market (Companion diagnostic, targeted cancer therapeutic, medical technology, pharmacogenomics, consumer genomics, molecular diagnostics) - By Therapy (Cancer, Cardiovascular, Infectious Disease) A wealth of financial data & business strategy information is provided including: - Company financials, sales & revenue figures - Business Model Strategies for Diagnostic, Pharmaceutical and Biotechnology Companies - Business Model Strategies for Providers. Provider Systems and Academic Medical Centres - Business Model Strategies for Payers & Governments - Private and Public Funding and Personalized Medicine Reimbursement - Revisions to Current Payment Systems and intellectual property - How to Gain Market Penetration in the EU - Cost-effectiveness and Business Value of Personalized Medicine - Therapeutics and Companion Diagnostics (e.g., BRAC Analysis, Oncotype Dx , KRAS Mutations) - Comprehensive account of company product portfolios & kits SWOT, Economic & Regulatory Environment specifics include: - Key strengths, weaknesses and threats influencing leading player position within the market - Technologies driving the market (e.g., New-Generation Sequencing Technologies, Ultra-High Throughput Sequencing) - Top fastest growing market segments and emerging opportunities - Top pharmaceutical companies within the IPM by market share and revenue - Comprehensive product portfolios, R&D activity and pipeline therapeutics - M&A activity and future strategies of top personalized medicine pharmacos - Personalized Medicine Regulation ( USA , UK, Germany , France , Spain , Italy ) - CE-marked Personalized Medicine/Diagnostic Tests - FDA Advances in Personalized Medicine Regulation This report highlights a number of significant pharmacos and gives details of their operations, products, financials and business strategy:- 23andMe", "external_links": [], "published": "2015-10-12T20:04:00.000+03:00", "crawled": "2015-10-13T01:50:26.429+03:00", "highlightTitle": ""}